Automated bone scan index as predictors of survival in prostate cancer

Abstract

Prostate cancer (PCa) is the second most diagnosed cancer in men. Early diagnosis and right management of PCa is critical to reducing deaths; the life expectancy is the main factors to be considered in the management of PCa. Among patients who die from PCa, the incidence of skeletal involvement appears to be >85%. Bone scan (BS) is the most common method for monitoring bone metastases in patients with PCa. The extent of bone metastasis was also associated with patient survival until now there is no clinically useful technique for measuring bone tumors and includes this information in the risk assessment. An alternative approach is to calculate a BS index (BSI) and it has shown clinical significance as a prognostic imaging biomarker. Some computer-assisted diagnosis (CAD) systems have been developed to measure BSI and are now available. The aim of this study was to investigate automated BSI (aBSI) measurements as predictors’ survival in PCa. Retrospectively cohort studied fifty patients with PCa who had undergone BS between January 2010 and December 2011 at our institution. All data collected was updated up to August 2016. CAD system analyzing BS images to automatically compute BSI measurements. Patients were stratified into three BSI categories BSI value 0, BSI value ≤1 and BSI value >1. Kaplan–Meier estimates of the survival function and the log-rank test were used to indicate a significant difference between groups stratified in accordance with the BSI values. A total of 35 subjects deaths were registered, with a median survival time 36 months after the follow-up BS of 5 years. Subjects with low aBSI value had longer overall survival in comparison with the other subjects (P = 0.004). aBSI measurements were shown to be a strong prognostic survival indicator in PCa; survival is poor in high-BSI value.

Survival and prognostic determinants of prostate cancer patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A retrospective cohort study

“…Moreover, patients with bone metastasis have a lower survival rate compared to those with no bone involvement. This finding is consistent with the study conducted in Indonesia, which compares survival based on a bone scan index measurement and found, patients with high bone scan index values have lower survival [16,17].…”

Comparison of 68Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer

“…On BS, MDP is incorporated into the hydroxyapatite matrix of bone in proportion to osteoblastic activity and allows the visualization of bone lesions. The tumour volume on a BS can be quantified with bone scan index (BSI) (Ulmert et al 2012 ; Nakajima et al 2017 ), an independent prognostic biomarker of survival (Ali et al 2020 ; Wiyanto et al 2017 ; Armstrong et al 2018 ; Miyoshi et al 2017 ). Currently, conventional BS is still considered the international standard and recommended in the guidelines for management of PCa patients with bone metastasis (Cornford et al 2017 ; Mottet et al 2017 ).…”

Comparison of PSMA PET/CT With Fluoride PET/CT for Detection of Bone Metastatic Disease in Prostate Cancer

“…On BS, MDP is incorporated into the hydroxyapatite matrix of bone in proportion to osteoblastic activity and allows the visualization of bone lesions. The tumour volume on a BS can be quanti ed with bone scan index (BSI) [8,9], an independent prognostic biomarker of survival [10][11][12][13]. Currently, conventional BS is still considered the international standard and recommended in the guidelines for management of PCa patients with bone metastasis [14,15].…”

“…With respect to other PET tracers, accuracy of 18 F-or 11 C-choline PET/CT in detection of bone lesions was identical but with higher speci city compared to uoride PET/CT [16,19]. Further, choline-PET/CT showed promising results for the early detection of bone metastasis [16].…”